Zhang, Kai <br/><br/>
CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.  [electronic resource] 

 -  Cancer letters  04 2019 
 - 130-140 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2019.01.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acrylamides--pharmacology<br/>Aminoquinolines--pharmacology<br/>Animals<br/>Apoptosis--drug effects<br/>Breast Neoplasms--drug therapy<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Line, Tumor<br/>Cell Proliferation<br/>Cyclin-Dependent Kinase 4--antagonists & inhibitors<br/>Cyclin-Dependent Kinase 6--antagonists & inhibitors<br/>Female<br/>G1 Phase--drug effects<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Piperazines--pharmacology<br/>Pyridines--pharmacology<br/>Receptor, ErbB-2--genetics<br/>Resting Phase, Cell Cycle--drug effects<br/>Xenograft Model Antitumor Assays--methods